Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Chimeric Therapeutics Ltd

Healthcare AU CHM

0.002AUD
-(-%)

Last update at 2026-03-10T22:59:00Z

Day Range

0.0020.002
LowHigh

52 Week Range

0.0010.009
LowHigh

Fundamentals

  • Previous Close 0.002
  • Market Cap8.84M
  • Volume2500000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.27597M
  • Revenue TTM9.75M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM 8.90M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -10.31962M -16.28001M -25.40756M -14.45995M -15.11371M
Minority interest - - - - -
Net income -10.43042M -12.52985M -25.50038M -14.62367M -15.11371M
Selling general administrative 7.05M 9.00M 14.88M 8.73M 5.82M
Selling and marketing expenses - 0.57M - - 0.15M
Gross profit 3.12M 7.45M - - 0.00265M
Reconciled depreciation 1.03M 1.01M 0.97M 0.95M 0.00263M
Ebit -10.10858M -12.30591M -24.98147M -13.81776M -15.10783M
Ebitda -9.07653M -11.29978M -23.66837M -12.86800M -15.10520M
Depreciation and amortization 1.03M 1.01M - 0.95M 0.00263M
Non operating income net other - - - - -
Operating income -15.11146M -12.30968M -25.40756M -13.81776M -15.10783M
Other operating expenses 19.08M 19.77M - 17.19M 14.85M
Interest expense 0.21M 0.33M 0.85M 0.64M 0.00588M
Tax provision 0.11M 0.00968M 0.09M 0.16M 0.00000M
Interest income 0.05M 0.12M 0.03M 0.01M 0.00265M
Net interest income -0.16302M -0.21050M -0.74628M -0.62715M -0.00588M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.11M -3.75016M 0.09M 0.16M -0.25791M
Total revenue 3.97M 7.46M 0.00000M 0.00000M 0.00265M
Total operating expenses 18.23M 19.77M - 17.19M 14.85M
Cost of revenue 0.85M 0.00392M - - -
Total other income expense net 4.79M -3.97034M 4.83M 3.36M -0.26379M
Discontinued operations - - - - -
Net income from continuing ops -10.43042M -12.52985M -25.50038M -14.62367M -15.11371M
Net income applicable to common shares -10.43042M -12.52985M -25.91689M -15.89840M -15.11371M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 21.57M 15.27M 22.49M 34.88M 36.50M
Intangible assets 11.04M - 12.98M 13.65M 13.83M
Earning assets - - - - -
Other current assets 0.22M 0.08M 0.33M 0.13M 0.23M
Total liab 19.60M 12.80M 16.41M 9.17M 11.37M
Total stockholder equity 1.97M 2.47M 6.08M 25.71M 25.13M
Deferred long term liab - - - - -
Other current liab 3.56M 6.90M 3.52M 4.32M 5.32M
Common stock - 63.51M 53.93M 51.81M 37.37M
Capital stock 70.16M - 53.93M 51.81M 37.37M
Retained earnings -76.33400M -66.55956M -56.78081M -29.58920M -15.17772M
Other liab - - 2.02M 0.15M 4.02M
Good will - - - - -
Other assets - - - 0.04M -
Cash 5.76M 3.05M 2.36M 18.38M 22.41M
Cash and equivalents - - - 18.38M 22.41M
Total current liabilities 14.61M 10.10M 14.69M 9.02M 7.35M
Current deferred revenue - - - - -
Net debt - -3.05300M - -18.38153M -22.41020M
Short term debt - - - 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - - - - 3.68M
Other stockholder equity - - 8.51M -0.87866M 2.94M
Property plant equipment - - 0.00560M 0.02M 0.01M
Total current assets 10.53M 3.22M 9.35M 21.17M 22.67M
Long term investments - - 0.04M 0.04M -
Net tangible assets - - -7.31792M 12.05M 11.30M
Short term investments - - - - -
Net receivables - 0.09M 3.65M 3.54M 0.02M
Long term debt - - - 0.00000M 3.68M
Inventory - - - -0.88213M -
Accounts payable 6.57M 3.20M 7.41M 4.70M 2.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 5.52M - 4.37M 2.94M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 12.05M - - -
Deferred long term asset charges - - - - -
Non current assets total 11.04M 12.05M 13.02M 13.71M 13.84M
Capital lease obligations - - - - -
Long term debt total - - - 0.00000M 3.68M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.00000M 0.00000M -0.11219M -0.04000M -0.04000M
Change to liabilities - - 4.74M 0.32M 2.59M
Total cashflows from investing activities - - -0.11219M -0.57786M -5.30704M
Net borrowings - -2.27700M -2.22500M -4.04682M -0.03401M
Total cash from financing activities 10.05M 8.26M 0.25M 9.50M 36.54M
Change to operating activities - - 0.10M 0.10M -0.23062M
Net income -10.43042M -12.52985M -25.91689M -15.89840M -15.11371M
Change in cash 2.70M 0.69M -16.01888M -4.02867M 22.41M
Begin period cash flow 3.05M 2.36M 18.38M 22.41M 0.00010M
End period cash flow 5.76M 3.05M 2.36M 18.38M 22.41M
Total cash from operating activities -7.27573M -7.53772M -16.30575M -13.15289M -8.83273M
Issuance of capital stock 8.20M 11.74M 2.58M 14.90M 39.30M
Depreciation 1.03M 1.01M 0.97M 0.95M 0.85M
Other cashflows from investing activities - -7.54784M 0.00000M 0.01M 0.00265M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.01280M 3.56M -0.99337M -2.63352M -0.02425M
Sale purchase of stock -0.57201M -1.19638M 2.58M -1.30866M -2.71505M
Other cashflows from financing activities 2.41M -0.01011M -0.09912M -0.56488M 0.85M
Change to netincome - - 4.80M 4.01M 3.10M
Capital expenditures 0.00000M 7.55M 0.11M 0.54M 5.31M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.21418M 1.60M 3.53M -0.00342M -
Stock based compensation 1.09M 0.57M - - -
Other non cash items 1.25M 1.81M - - -
Free cash flow -7.27573M 0.01M -16.41795M -0.53785M -5.30704M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CHM
Chimeric Therapeutics Ltd		 - -% 0.002 - - 0.91 4.48 2.36 -2.1391
CSL
CSL Ltd		 -1.98 1.37% 142.58 16.70 19.49 4.61 2.68 3.87 11.63
TLX
TELIX Pharmaceuticals Ltd		 -0.24 2.18% 10.76 - 1000.00 4.25 5.68 3.34 76.39
MSB
Mesoblast Ltd		 0.01 0.46% 2.19 - 454.55 43.02 3.19 28.08 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.2 1.57% 12.55 53.70 45.66 24.19 4.61 19.56 57.40

Reports Covered

Stock Research & News

View All

Profile

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Chimeric Therapeutics Ltd

62 Lygon Street, Carlton, VIC, Australia, 3053

Key Executives

Name Title Year Born
Ms. Jennifer Chow CEO, MD & Director NA
Mr. Eliot Bourk Chief Bus. Officer & Head of External Innovation NA
Dr. Li Ren VP of Technical Operations NA
Mr. Kelly R. Thornburg VP & Head of Quality 1963
Mr. Jason B. Litten M.D. Chief Medical Officer 1974
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBA Sec. 1961
Mr. Nathan Jong C.A. Company Sec. NA
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Founder & Executive Chairman 1956
Mr. Eliot Bourk Chief Business Officer & Head of External Innovation NA
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO, Joint Company Secretary & Director 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.